ArticleGenes & diseases2019
Upregulation of the
Article in Genes & diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Anticancer potential of Curcuma caesia: induction of DNA damage and apoptosis in cervical cancer.BMC complementary medicine and therapies · 2026Article
- Expression of miRNAs Associated With Embryo Development and DNA Damage Response in Porcine Embryos.Molecular reproduction and development · 2025Article
- MicroRNAs: Novel clinical biomarkers for cancer radiotherapy (Review).Molecular medicine reports · 2025Review
- Knocking Down HN1 Blocks Helicobacter pylori-Induced Malignant Phenotypes in Gastric Mucosal Cells and Inhibits Gastric Cancer Cell Proliferation, Cytoskeleton Remodeling, and Migration.Biochemical genetics · 2025Article
- Targeting APE1: Advancements in the Diagnosis and Treatment of Tumors.Protein and peptide letters · 2025Review
- Ferroptosis: opening up potential targets for gastric cancer treatment.Molecular and cellular biochemistry · 2024Review
- Current study of pathogenetic mechanisms and therapeutics of chronic atrophic gastritis: a comprehensive review.Frontiers in cell and developmental biology · 2024Review
- Revisiting Two Decades of Research Focused on Targeting APE1 for Cancer Therapy: The Pros and Cons.Cells · 2023Review
- Levels of APE1 Repair Gene and CLEC4M in Lung Cancer Patients Receiving Cisplatin Chemotherapy.Archives of Razi Institute · 2023Article
- SIRT1/APE1 promotes the viability of gastric cancer cells by inhibiting p53 to suppress ferroptosis.Open medicine (Warsaw, Poland) · 2023Article
- Investigations into the impact of non-coding RNA on the sensitivity of gastric cancer to radiotherapy.Frontiers in physiology · 2023Review
- APE1 assembles biomolecular condensates to promote the ATR-Chk1 DNA damage response in nucleolus.Nucleic acids research · 2022Article
- Downregulation ofWorld journal of gastroenterology · 2022Article
- miR-5188 augments glioma growth, migration and invasion through an SP1-modulated FOXO1-PI3K/AKT-c-JUN-positive feedback circuit.Journal of cellular and molecular medicine · 2020Article
- SPEN induces miR-4652-3p to target HIPK2 in nasopharyngeal carcinoma.Cell death & disease · 2020Article
- Genomic alterations and abnormal expression of APE2 in multiple cancers.Scientific reports · 2020Article
- Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF-κB signaling pathway.Cancer cell international · 2020Article
- Hypoxia Induces Mitochondrial Defect That Promotes T Cell Exhaustion in Tumor Microenvironment Through MYC-Regulated Pathways.Frontiers in immunology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer remains one of the leading causes of cancer-related death worldwide, and most of the cases are associated with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.